NCI Center for Cancer Research shared a post on LinkedIn:
“BREAKTHROUGH IN TREATMENT: In 2012, Senior Investigator Ira Pastan, M.D., tested the immunotoxin moxe for patients with relapsed or refractory hairy cell leukemia (HCL).
As a result, the drug is now an FDA approved therapy for the disease if it has recurred or progressed after at least two prior systemic therapies.
Read more.”